Fabio Cataldi - 05 Sep 2022 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Chief Medical Officer
Signature
/s/ Gregory Oakes, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
05 Sep 2022
Net transactions value
$0
Form type
4
Filing time
07 Sep 2022, 17:09:49 UTC
Next filing
02 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Employee Stock Option (right to buy) Award $0 +400,000 $0.000000 400,000 05 Sep 2022 Common Stock 400,000 $0.8900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares of common stock underlying this option will vest and become exercisable on September 5, 2023 and the remaining shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.